{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:07:16Z","timestamp":1762272436815},"reference-count":85,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharm. Pat. Anal."],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.4155\/ppa-2019-0016","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T10:03:27Z","timestamp":1571133807000},"page":"175-191","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Secondary Patents: Innovator and Generic Strategies"],"prefix":"10.1080","volume":"8","author":[{"given":"Saritha","family":"Kiran","sequence":"first","affiliation":[{"name":"CSIR URDIP Tapovan NCL Campus Pune\rMaharashtra\rIndia"},{"name":"Academy of Scientific & Innovative Research (AcSIR) Intellectual property Ghaziabad\rUttar Pradesh\rIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivakami","family":"Dhulap","sequence":"additional","affiliation":[{"name":"CSIR URDIP Tapovan NCL Campus Pune\rMaharashtra\rIndia"},{"name":"Academy of Scientific & Innovative Research (AcSIR) Intellectual property Ghaziabad\rUttar Pradesh\rIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"CSIR URDIP Tapovan NCL Campus Pune\rMaharashtra\rIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0654-9"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0737-6782.2004.00075.x"},{"issue":"3","key":"e_1_3_2_5_1","first-page":"226","article-title":"The art of using secondary patents to improve protection International","volume":"3","author":"Burdon M","year":"2003","unstructured":"Burdon M , SloperK. The art of using secondary patents to improve protection International. J. Health Care Mark.3(3), 226\u2013238 (2003).","journal-title":"J. Health Care Mark."},{"key":"e_1_3_2_6_1","volume-title":"Making the Most of Each and Every Brand.","author":"Ellery T","year":"2012","unstructured":"Ellery T , HansenN. Pharmaceutical Life Cycle Management. In: Making the Most of Each and Every Brand.John Wiley & Sons, INC publication, NJ, USA (2012)."},{"issue":"3","key":"e_1_3_2_7_1","first-page":"389","article-title":"Special patent provisions for Pharmaceuticals: have they outlived their Usefulness? A political, legislative and legal history of U. S. law and observations for the future","volume":"39","author":"Engelberg AB","year":"1999","unstructured":"Engelberg AB . Special patent provisions for Pharmaceuticals: have they outlived their Usefulness? A political, legislative and legal history of U. S. law and observations for the future. IDEA39(3), 389\u2013432 (1999).","journal-title":"IDEA"},{"key":"e_1_3_2_8_1","article-title":"IP strategies and policies for and against evergreening","author":"Granstrand O","year":"2014","unstructured":"Granstrand O , TietzeF. IP strategies and policies for and against evergreening. Eur. Policy Intell. Prop.Presented at: The conference CIM Working Paper (2014). https:\/\/www.ifm.eng.cam.ac.uk\/research\/ctm\/ctmpublications\/ctmworkingpapers\/ip-strategies-and-policies-for-and-against-evergreening\/","journal-title":"Eur. Policy Intell. Prop."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2006.088"},{"key":"e_1_3_2_10_1","unstructured":"Kiran Kulkarni. Paper under revision in IJIPM journal Inderscience publications (2017). https:\/\/www.ifm.eng.cam.ac.uk\/research\/ctm\/ctmpublications\/ctmworkingpapers\/ip-strategies-and-policies-for-and-against-evergreening\/"},{"key":"e_1_3_2_11_1","unstructured":"Matthew Herper Healthcare. https:\/\/www.forbes.com\/sites\/matthewherper\/2017\/10\/16\/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad\/#c1df6592d459"},{"key":"e_1_3_2_12_1","unstructured":"Haessle AB US4255431 (1981)."},{"key":"e_1_3_2_13_1","unstructured":"Haessle AB [SE ] US4508905 (1985)."},{"key":"e_1_3_2_14_1","unstructured":"Haessle AB US4045563 (1977)."},{"key":"e_1_3_2_15_1","unstructured":"Haessle AB US4786505 (1988)."},{"key":"e_1_3_2_16_1","unstructured":"Haessle AB US4853230 (1989)."},{"key":"e_1_3_2_17_1","unstructured":"Haessle AB US5093342 (1992)."},{"key":"e_1_3_2_18_1","unstructured":"Astra AB [SE ] US5599794 (1997)."},{"key":"e_1_3_2_19_1","unstructured":"Astra AB [SE ] US6150380 (2000)."},{"key":"e_1_3_2_20_1","unstructured":"Astra AB [SE ] US5753265 (1998)."},{"key":"e_1_3_2_21_1","unstructured":"Merck & Co Inc [USA ] US6166213 (2000)."},{"key":"e_1_3_2_22_1","unstructured":"Merck & Co Inc [US ] US6147103 (2011)."},{"key":"e_1_3_2_23_1","unstructured":"Astrazeneca AB [SE ] US6403616 (2002)."},{"key":"e_1_3_2_24_1","unstructured":"Merck & Co Inc [US ] US6191148 (2001)."},{"key":"e_1_3_2_25_1","unstructured":"Astra AB [SE ] US5817338 (1998)."},{"key":"e_1_3_2_26_1","unstructured":"In Re Omeprazole Litigation (S.D.N.Y. 1999)."},{"key":"e_1_3_2_27_1","unstructured":"In Re: Omeprazole (S.D.N.Y.) (Fed. Cir. 2003)."},{"key":"e_1_3_2_28_1","unstructured":"Haessle AB [SE ] US4636499 (1987)."},{"key":"e_1_3_2_29_1","unstructured":"Haessle AB [SE ] US4738974 (1988)."},{"key":"e_1_3_2_30_1","unstructured":"Astra AB [Se ] US5900424 (1999)."},{"key":"e_1_3_2_31_1","unstructured":"Astra AB [SE ] US5714504 (1998)."},{"key":"e_1_3_2_32_1","unstructured":"Astrazeneca AB [SE ] US6369085 (2002)."},{"key":"e_1_3_2_33_1","unstructured":"Astra AB [SE ] US5690960 (1997)."},{"key":"e_1_3_2_34_1","unstructured":"Astrazeneca AB [SE ] US6428810 (2002)."},{"key":"e_1_3_2_35_1","unstructured":"Astra AB [SE ] US5629305 (1997)."},{"key":"e_1_3_2_36_1","unstructured":"Astra Aktiebolag US5877192 (1999)."},{"key":"e_1_3_2_37_1","unstructured":"Astrazeneca AB US7411070 (2008)."},{"key":"e_1_3_2_38_1","unstructured":"Astrazeneca AB US8466175 (2013)."},{"key":"e_1_3_2_39_1","unstructured":"Astra Aktiebolag US5589491 (1996)."},{"key":"e_1_3_2_40_1","unstructured":"Astrazeneca AB [SE] US6143771 (2000)."},{"key":"e_1_3_2_41_1","unstructured":"Astrazeneca AB [SE ] US6875872 (2005)."},{"key":"e_1_3_2_42_1","unstructured":"Astra Aktiebolag US5877192 (1999)."},{"key":"e_1_3_2_43_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US4628098 (1986)."},{"key":"e_1_3_2_44_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US4689333 (1987)."},{"key":"e_1_3_2_45_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US5045321 (1991)."},{"key":"e_1_3_2_46_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US5026560 (1991)."},{"key":"e_1_3_2_47_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US5013743 (1991)."},{"key":"e_1_3_2_48_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US5093132 (1991)."},{"key":"e_1_3_2_49_1","unstructured":"Takeda Chemical Industries Ltd [Jp ] US5433959 (1995)."},{"key":"e_1_3_2_50_1","unstructured":"Takeda Pharmaceutical [Jp ] US7399485 (2008)."},{"key":"e_1_3_2_51_1","unstructured":"Takeda Pharmaceutical [Jp ] US7431942 (2008)."},{"key":"e_1_3_2_52_1","unstructured":"Prographarm Lab [Fr ] US5464632 (1995)."},{"key":"e_1_3_2_53_1","unstructured":"Takeda Chemical Industries Ltd [USA ] US6328994 (2001)."},{"key":"e_1_3_2_54_1","unstructured":"Takeda Pharmaceutical [JP ] US7396841 (2008)."},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","unstructured":"Takeda Chemical Industries Ltd [JP ] US6462058 (2002).","DOI":"10.3833\/pdr.v2002i25.1053"},{"key":"e_1_3_2_56_1","unstructured":"Takeda Pharmaceutical [JP ] Us6939971 (2005)."},{"key":"e_1_3_2_57_1","unstructured":"Takeda Pharmaceutical [JP ] Us7285668 (2007)."},{"key":"e_1_3_2_58_1","unstructured":"Takeda Chemical Industries Ltd [JP ] US6664276 (2003)."},{"key":"e_1_3_2_59_1","unstructured":"Takeda Pharmaceutical [JP ] US8105626 (2012)."},{"key":"e_1_3_2_60_1","unstructured":"Takeda Pharmaceutical [JP ] US7790755 (2010)."},{"key":"e_1_3_2_61_1","unstructured":"Takeda Pharmaceuticals USA Inc [USA ] US8461187 (2013)."},{"key":"e_1_3_2_62_1","unstructured":"Takeda Pharmaceutical [JP ] US8871273 (2014)."},{"key":"e_1_3_2_63_1","unstructured":"Takeda Pharmaceuticals USA Inc. [USA ] US8173158 (2012)."},{"key":"e_1_3_2_64_1","unstructured":"Takeda Pharmaceutical [J[P]] US8722084 (2014)."},{"key":"e_1_3_2_65_1","unstructured":"Takeda Pharmaceutical [JP ] US8784885 (2014)."},{"key":"e_1_3_2_66_1","unstructured":"Takeda Pharmaceutical [JP ] US9011926 (2015)."},{"key":"e_1_3_2_67_1","unstructured":"Takeda Pharmaceuticals USA Inc . US9233103 (2016)."},{"key":"e_1_3_2_68_1","unstructured":"Takeda Pharmaceuticals USA Inc. US9238029 (2016)."},{"key":"e_1_3_2_69_1","unstructured":"Takeda Pharmaceutical [JP ] US9145389 (2015)."},{"key":"e_1_3_2_70_1","unstructured":"Takeda Pharmaceutical [JP ] US9241910 (2016)."},{"key":"e_1_3_2_71_1","unstructured":"Eisai Co Ltd [JP ] US5045552 (1991)."},{"key":"e_1_3_2_72_1","unstructured":"Eisai Co Ltd [JP ] US5035899 (1991)."},{"key":"e_1_3_2_73_1","article-title":"The Lead Compound Analysis For Chemical Obviousness: Uspto V. The Courts","author":"Nichols JM","year":"2014","unstructured":"Nichols JM , CarrollWA. The Lead Compound Analysis For Chemical Obviousness: Uspto V. The Courts. Ipo Law J. (2014).","journal-title":"Ipo Law J."},{"key":"e_1_3_2_74_1","volume-title":"566 F.3d 999, 1008-09 (Fed. Cir. 2009)","author":"Altana Pharma Ag V. Teva Pharma.","unstructured":"Altana Pharma Ag V. Teva Pharma. USA 566 F.3d 999, 1008-09 (Fed. Cir. 2009)."},{"key":"e_1_3_2_75_1","unstructured":"Eisai Co Ltd [Jp ] Us5916904 (1999)."},{"key":"e_1_3_2_76_1","unstructured":"Byk Gulden Lomberg Chem Fab [DE ] US4758579 (1988)."},{"key":"e_1_3_2_77_1","unstructured":"Byk Gulden Lomberg Chem Fab [DE ] US4555518 (1985)."},{"key":"e_1_3_2_78_1","unstructured":"Byk Gulden Lomberg Chem Fab [DE ] US5997903 (1999)."},{"key":"e_1_3_2_79_1","unstructured":"Altana Pharma Ag [De ] US6780881 (2003)."},{"key":"e_1_3_2_80_1","unstructured":"Altana Pharma Ag [De ] US7351723 (2000)."},{"key":"e_1_3_2_81_1","doi-asserted-by":"crossref","unstructured":"Nycomed Gmbh US8754108 (2000).","DOI":"10.1016\/S0294-3506(00)88767-0"},{"key":"e_1_3_2_82_1","doi-asserted-by":"crossref","unstructured":"Case: 1:08-Cv-02871 Document #: 1 Filed: 16 May 2008.","DOI":"10.5089\/9781451822953.002"},{"key":"e_1_3_2_83_1","unstructured":"Wyeth Llc [USA ] US7838027 (2010)."},{"key":"e_1_3_2_84_1","unstructured":"Wyeth Corp [USA ] US7544370 (2009)."},{"key":"e_1_3_2_85_1","unstructured":"Wyeth Corp [USA ] US7550153 (2009)."},{"key":"e_1_3_2_86_1","unstructured":"Wyeth Corp [USA ] US7553498 (2009)."},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2018.1424134"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa-2019-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:05:42Z","timestamp":1715976342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa-2019-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.4155\/ppa-2019-0016"],"URL":"https:\/\/doi.org\/10.4155\/ppa-2019-0016","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}